Liste Artikel Personalverkauf 12/2017

Total Page:16

File Type:pdf, Size:1020Kb

Liste Artikel Personalverkauf 12/2017 Spital-Pharmazie Liste Artikel Personalverkauf 12/2017 komplett alphabetisch (Swissmedic-Kat. A und B nur für Medizinalpersonen) Seite 1 von 72 Liste Personalverkauf komplett - Stand: 12/2017 3T SAP-Nr. Name - Stärke - Packungsgrösse Swissmedic Wirkstoff - Menge - 9063315 3TC Filmtabl 300 mg 30 Stk A Lamivudin 300 mg 9008596 3TC Trink Lös 10 mg/ml o alkohol 240 ml A 15 ml enth. Lamivudin 150 mg 9138121 ABILIFY MAINTENA Depot 400 mg Fsp B 2 ml enth. Aripiprazol 400 mg 9138969 ACICLOVIR Labatec Tr.Sub. 250 mg 5x10ml A Aciclovir 250 mg 9117810 ACIDUM FOLICUM Hänseler Tabl 5 mg 100 St B Folsäure 5 mg 9076655 ACLASTA Inf Lös 5 mg/100ml Amp 100 ml B 100 ml enth. Zoledronsäure 5 mg 9087589 ACTEMRA Inf Konz 80 mg/4ml Durchstf 4 ml A 4 ml enth. Tocilizumab 80 mg 9087587 ACTEMRA InfKonz 200mg/10ml Durchstf 10ml A 10 ml enth. Tocilizumab 200 mg 9087588 ACTEMRA InfKonz 400mg/20ml Durchstf 20ml A 20 ml enth. Tocilizumab 400 mg 9023189 ACTILYSE Trockensub 10 mg c Solv Amp B 10 ml enth. Alteplase 10 mg 9079999 ACTILYSE Trockensub 20mg c Solv 1 Amp B 20 ml enth. Alteplase 20 mg 4000302 ACTILYSE Trockensub 50 mg c Solv 1 Amp B 50 ml enth. Alteplase 50 mg 9050746 ACTOS Tabl 15 mg 28 Stk B Pioglitazon 15 mg 9114502 ADRENALIN Bichsel Inj 0.1 mg/ml 10x10ml B 10 ml enth. Adrenalin (Epinephrin) 1 mg 9102359 ADRENALIN Sint InjLös 0.1mg/ml 10Amp 1ml B 1 ml enth. Adrenalin (Epinephrin) 0.1 mg 9103364 ADRENALIN Sint InjLös 1mg/ml 10 Amp 1ml B 1 ml enth. Adrenalin (Epinephrin) 1 mg 9090812 ADRIBLASTIN SOL InjPräp 50mg Cytosafe2St A 25 ml enth. Doxorubicin hydrochlorid 50 mg 9012496 ADVANTAN Creme 0.1 % 50 g B 1 g enth. Methylprednisolon aceponat 1 mg 9007763 ADVANTAN Salbe 0.1 % 50 g B 1 g enth. Methylprednisolon aceponat 1 mg 4000310 AETHOXYSKLEROL Inj Lös 0.5 % 5 Amp 2 ml B 1 ml enth. Polidocanol 600 5 mg Seite 2 von 72 Liste Personalverkauf komplett - Stand: AE SAP-Nr. Name - Stärke - Packungsgrösse Swissmedic Wirkstoff - Menge - 9058291 AETHYLCHLORID Sintetica Spray 100 g B Chlorethan 100 g 9048861 AGGRASTAT InfLös 12.5mg/250ml Btl. 250ml A 250 ml enth. Tirofiban 12.5 mg 4001861 AKINETON Inj Lös 5 mg/ml 5 Amp 1 ml B 1 ml enth. Biperiden lactat 5 mg, Biperiden lactat 5 mg 4003195 AKINETON retard Ret Tabl 4 mg 30 Stk B Biperiden hydrochlorid 4 mg 4001862 AKINETON Tabl 2 mg 50 Stk B Biperiden hydrochlorid 2 mg 9008447 ALCAINE Gtt Opht 15 ml B 1 ml enth. Proxymetacain hydrochlorid 5 mg 4002117 ALDACTONE Filmtabl 100 mg 100 Stk B Spironolacton 100 mg 4002115 ALDACTONE Filmtabl 25 mg 100 Stk B Spironolacton 25 mg 4002116 ALDACTONE Filmtabl 50 mg 50 Stk B Spironolacton 50 mg 9134197 ALENDRONAT Spirig HC Wochentab 70mg 4 St B Alendronsäure 70 mg 9120602 ALGIFOR Junior Susp 100 mg/5ml 200 ml B 5 ml enth. Ibuprofen 100 mg 9090808 ALIMTA Trockensub 500mg für Inf Lös 1Stk A Pemetrexed 500 mg 9058276 ALKERAN Filmtabl 2 mg 25 Stk A Melphalan 2 mg 9090809 ALKERAN Trockensub 50 mg c Solv Amp A 10 ml enth. Melphalan 50 mg 9022552 ALPHAGAN Gtt Opht 0.2 % 5 ml B 1 ml enth. Brimonidin tartrat 2 mg, Brimonidin tartrat 2 mg 9044997 ALUCOL GEL Susp Frucht Fl 130 ml D 5 ml enth. Aluminiumoxid, wasserhaltig (Algeldrat) 375 mg, Magnesiumhydroxid 175 mg 9081521 ALVESCO Dosieraeros 160 mcg 120 Dos B Ciclesonid 160 mcg 9016461 AMARYL Tabl 2 mg 30 Stk B Glimepirid 2 mg 9047059 AMBISOME Trockensub 50 mg Durchstf 10 St A Amphotericin B 50 mg 4002543 AMIKIN Inj Lös 500mg/2ml 5 Stechamp 2ml A 2 ml enth. Amikacin 500 mg Seite 3 von 72 Liste Personalverkauf komplett - Stand: 12/2017 AM SAP-Nr. Name - Stärke - Packungsgrösse Swissmedic Wirkstoff - Menge - 9112288 AMLODIPIN Sandoz eco Tabl 10 mg 30 Stk B Amlodipin 10 mg 9108001 AMLODIPIN Sandoz eco Tabl 5 mg 30 Stk B Amlodipin 5 mg 9086432 AMOXICILLIN Sandoz Disp Tabl 1000mg 20St A Amoxicillin 1 g 9086431 AMOXICILLIN Sandoz Disp Tabl 750mg 20 St A Amoxicillin 750 mg 9086430 AMOXICILLIN Sandoz Susp 200mg/4ml 100ml A 4 ml enth. Amoxicillin 200 mg 4002600 AMPHO MORONAL Susp 10 % 24 ml B 1 ml enth. Amphotericin B 100 mg, Amphotericin B 100 mg 9134362 AMPHO-MORONAL Lutschtabl 10 mg 20 Stk B Amphotericin B 10 mg 9135644 AMPRES Inj Lös 30 mg/ml Durchstf 20 ml B 20 ml enth. Chloroprocain hydrochlorid 600 mg 9090910 AMSIDYL Inf Konz 85mg Amp 6 Stk A 13.5 ml enth. Amsacrin 85 mg 4001832 ANAFRANIL Drag 25 mg 30 Stk B Clomipramin hydrochlorid 25 mg, Clomipramin hydrochlorid 25 mg 4003066 ANAFRANIL SR Divitabs 75 mg 20 Stk B Clomipramin hydrochlorid 75 mg 4002601 ANCOTIL Inf Lös 1 % 5 x 250 ml B 1 ml enth. Flucytosin 10 mg 9101929 ANGIOX Trockensub 250 mg Durchstf 10 Stk B Bivalirudin 250 mg 4000363 ANTABUS Disperg 400 mg 50 Stk B Disulfiram 400 mg 9047963 APHENYLBARBIT Streuli Tabl 15 mg 100 Stk B Phenobarbital 15 mg 9047961 APHENYLBARBIT Streuli Tabl 50 mg 100 Stk B Phenobarbital 50 mg 4003418 APRANAX Filmtabl 550 mg 50 Stk B Naproxen natrium 550 mg 9128011 APROKAM Trockensub 50 mg Durchstf 10 Stk A Cefuroxim 50 mg 9081054 APROVEL 150 Filmtabl 150 mg 28 Stk B Irbesartan 150 mg 9131305 ARANESP 100 mcg m Nadelschutz Fsp 4 Stk A 0.5 ml enth. Darbepoetin alfa 0.1 mg Seite 4 von 72 Liste Personalverkauf komplett - Stand: 12/2017 AR SAP-Nr. Name - Stärke - Packungsgrösse Swissmedic Wirkstoff - Menge - 9131001 ARANESP 30 mcg m Nadelschutz Fsp 4 Stk A 0.3 ml enth. Darbepoetin alfa 0.03 mg 9130942 ARANESP 50 mcg m Nadelschutz Fsp 4 Stk A 0.5 ml enth. Darbepoetin alfa 0.05 mg 9131317 ARANESP 500 mcg m Nadelschutz Fertspr A 1 ml enth. Darbepoetin alfa 0.5 mg 9131308 ARANESP 80 mcg m Nadelschutz Fsp 4 Stk A 0.4 ml enth. Darbepoetin alfa 0.08 mg 9029589 ARAVA Filmtabl 20 mg 30 Stk A Leflunomid 20 mg 9110159 ARCOXIA Filmtabl 30 mg 28 Stk B Etoricoxib 30 mg 9094303 ARCOXIA Filmtabl 60 mg 28 Stk B Etoricoxib 60 mg 9015396 ARICEPT Tabl 10 mg 28 Stk B Donepezil hydrochlorid 10 mg 9013104 ARICEPT Tabl 5 mg 28 Stk B Donepezil hydrochlorid 5 mg 9143487 ARIPIPRAZOL Mepha Tabl 10 mg 28 Stk B Aripiprazol 10 mg 9143488 ARIPIPRAZOL Mepha Tabl 15 mg 28 Stk B Aripiprazol 15 mg 9143469 ARIPIPRAZOL Mepha Tabl 5 mg 28 Stk B Aripiprazol 5 mg 9054534 ARIXTRA Inj Lös 2.5 mg 10Fertigspr 0.5ml B 0.5 ml enth. Fondaparinux natrium 2.5 mg 9077337 ARIXTRA Inj Lös 7.5mg 10 Fertigspr 0.6ml B 0.6 ml enth. Fondaparinux natrium 7.5 mg 4001693 ASPEGIC INJ Trockensub 0.5 g Vial 20 Stk B Acetylsalicylsäure 500 mg 9058897 ASPEGIC Plv 100 mg Btl 20 Stk D Acetylsalicylsäure 100 mg 9058801 ASPEGIC Plv 500 mg Btl 20 Stk D Acetylsalicylsäure 500 mg 9100881 ASPIRIN CARDIO Filmtabl 100 mg 98 Stk B Acetylsalicylsäure 100 mg 9019468 ASPIRIN CARDIO Filmtabl 300 mg 30 Stk B Acetylsalicylsäure 300 mg 9034820 ATACAND PLUS Tabl 16/12.5 mg 28 Stk B Candesartan cilexetil 16 mg, Hydrochlorothiazid 12.5 mg Seite 5 von 72 Liste Personalverkauf komplett - Stand: 12/2017 AT SAP-Nr. Name - Stärke - Packungsgrösse Swissmedic Wirkstoff - Menge - 9046401 ATACAND PLUS Tabl 8/12.5 mg 28 Stk B Candesartan cilexetil 8 mg, Hydrochlorothiazid 12.5 mg 9108360 ATACAND Tabl 16 mg 28 Stk B Candesartan cilexetil 16 mg 9031242 ATACAND Tabl 8 mg 28 Stk B Candesartan cilexetil 8 mg 4000390 ATARAX Filmtabl 25 mg 25 Stk B Hydroxyzin dihydrochlorid 25 mg 9113726 ATORVASTATIN Pfizer Filmtabl 10mg 30 St B Atorvastatin 10 mg 9113729 ATORVASTATIN Pfizer Filmtabl 20mg 30 Stk B Atorvastatin 20 mg 9113731 ATORVASTATIN Pfizer Filmtabl 40mg 30 Stk B Atorvastatin 40 mg 9144025 ATRACURIUM Labatec 25mg/2.5ml 5Amp 2.5ml B 2.5 ml enth. Atracurium besilat 25 mg 9096395 ATRIPLA Filmtabl 30 Stk A Efavirenz 600 mg, Emtricitabin 200 mg, Tenofovir disoproxil 245 mg 9131712 ATROPIN SULFAT Labatec 1mg/5ml 10FSP 5ml B 5 ml enth. Atropinsulfat 1 mg 4003853 ATROPINE SDU Faure GttOpht 0.5% 20x0.4ml B 1 ml enth. Atropinsulfat 5 mg 4002053 ATROPINUM SULF InjLös 0.5 mg/ml 10 Amp B 1 ml enth. Atropinsulfat 0.5 mg 9026526 ATROVENT Inhal Lös 0.25 mg/2ml 60 x 2 ml B 2 ml enth. Ipratropium bromid wasserfrei 0.25 mg 4003420 AURORIX Filmtabl 150 mg 30 Stk B Moclobemid 150 mg 9039159 AVALOX Filmtabl 400 mg 10 Stk A Moxifloxacin 400 mg 9118241 AVALOX Inf Lös 400 mg/250ml 250 ml A 250 ml enth. Moxifloxacin 400 mg 9090806 AVASTIN Inf Konz 400 mg/16ml Vial 16 ml A 16 ml enth. Bevacizumab 400 mg 9068550 AXOTIDE Dosierae 50mcg FCKW-frei 120 Dos B Fluticason propionat 50 mcg 9128296 AXURA Filmtabl 10 mg 50 Stk B Memantin hydrochlorid 10 mg 9019957 AZACTAM Trockensub 2 g Durchstf A Aztreonam 2 g Seite 6 von 72 Liste Personalverkauf komplett - Stand: 12/2017 AZ SAP-Nr. Name - Stärke - Packungsgrösse Swissmedic Wirkstoff - Menge - 9142125 AZITHROMYCIN Pfizer Filmtabl 250 mg 6 St A Azithromycin 250 mg 9117376 BACLOFEN Intrathecal 0.05mg/ml 10Amp 1ml B 1 ml enth. Baclofen 0.05 mg 9118939 BACLOFEN Intrathecal 10mg/20ml 5Amp 20ml B 20 ml enth. Baclofen 10 mg 9118938 BACLOFEN Intrathecal 10mg/5ml 10 Amp 5ml B 5 ml enth.
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su
    Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones By Ming-Hsiu Yang Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chairperson Ryan A. Altman Michael D. Clift Apurba Dutta Michael F. Rafferty Jon A. Tunge Date Defended: April 26, 2017 The Dissertation Committee for Ming-Hsiu Yang certifies that this is the approved version of the following dissertation: Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones Chairperson Ryan A. Altman Date Approved: April 26, 2017 ii Abstract Ming-Hsiu Yang Department of Medicinal Chemistry, April 2017 The University of Kansas Fluorine plays an important role in drug design, because of some unique features imparted by fluorine. The incorporation of fluorine into small molecules can modulate molecular physicochemical properties, metabolic stability, lipophilicity, and binding affinity to the target proteins. However, few fluorinated molecules are biosynthesized by enzymes. This means incorporating fluorine into the molecules relies on synthetic methods. Thus, efficient synthetic strategies to access the molecules bearing a variety of privileged fluorinated moieties are important for drug discovery. Fluoroalkenes are an isopolar and isosteric mimic of an amide bond with distinct biophysical properties, including decreased H-bond donating and accepting abilities, increased lipophilicity, and metabolic stability. Moreover, fluoroalkenes can also serve as probes for conducting conformational analyses of amides. These potential applications require the development of efficient methods to access fluoroalkenes. In chapter 2, a Shapiro fluorination strategy to access peptidomimetic fluoroalkenes is demonstrated.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • Review of the Regulation of Products at the Interface Between Cosmetics and Therapeutic Goods
    PO Box 100, Woden ACT 2606, Australia Review of the regulation of products at the interface between cosmetics and therapeutic goods 18 March 2005 Review of the regulation of products at the interface between cosmetics and therapeutic goods March 2005 Prepared for the TGA by David B Newgreen Review of the regulation of products at the interface between cosmetics and therapeutic goods CONTENTS ABBREVIATIONS ..........................................................................................................ii ACKNOWLEDGMENTS .............................................................................................. iii TERMS OF REFERENCE ..............................................................................................iv SUMMARY.....................................................................................................................vi RECOMMENDATIONS..................................................................................................x 1. INTRODUCTION ......................................................................................................13 2. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN AUSTRALIA AND NEW ZEALAND ....................................................................23 2.1 AUSTRALIA......................................................................................................23 2.2 NEW ZEALAND ...............................................................................................33 3. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Opinion of the Scientific Committee on Consumer Safety on O
    SCCS/1613/19 Final Opinion Version S Scientific Committee on Consumer Safety SCCS OPINION ON the safety of aluminium in cosmetic products Submission II The SCCS adopted this document at its plenary meeting on 03-04 March 2020 SCCS/1613/19 Final Opinion Opinion on the safety of aluminium in cosmetic products – submission II ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final versions SCCS members Dr U. Bernauer Dr L. Bodin (Rapporteur) Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven SCCS external experts Dr A. Koutsodimou Dr A. Simonnard Prof. W. Uter All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 16 December 2019 until 17 February 2020). Comments received during this time period are considered by the SCCS. For this Opinion, some changes occurred, in particular in sections 1, 3.2, 3.3.4.5, 3.3.8.1, 3.5, as well as in related discussion parts and conclusion (question 1). The list of references has also been updated.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids. It is notable that breast cysts, as for Antiperspiran breast cancers, start most frequently in the upper outer quadrant of the breast, which is the region closest to the site of underarm antiperspirant application. Mechanistic Copyright: © 2019 Philippa D Darbre. evidence is reviewed for a link between aluminium levels in breast tissue, cyst Clinical Dermatology: Research And Therapy. This is an open access article formation and development of breast cancer. If excessive use of antiperspirant is a distributed under the Creative cause of breast cysts, then reduction or cessation of use could provide a preventative Commons Attribution License, which or even treatment strategy. Furthermore, if cyst formation from antiperspirant use is permits unrestricted use, distribution, an indicator of increased risk for breast cancer, then reduction in use of antiperspirant and reproduction in any medium, provided the original work is properly could also provide a strategy for reducing breast cancer risk.
    [Show full text]
  • Queensland Poisons Information Centre Annual Report 2019
    Queensland Poisons Information Centre Annual Report 2019 13 11 26 www.childrens.health.qld.gov.au/poisonsinformationcentre Poisons Information Centre Queensland Children’s Hospital Pharmacy Department, Level 2 501 Stanley Street South Brisbane Qld 4101 Table of Contents Mission Statement ............................................................................................................................................................ 4 Services and Operation ..................................................................................................................................................... 4 Location ......................................................................................................................................................................... 4 Telephone Access .......................................................................................................................................................... 4 Hours of Operation ........................................................................................................................................................ 4 Website .......................................................................................................................................................................... 4 Personnel ....................................................................................................................................................................... 5 External Consultants .....................................................................................................................................................
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]